Real-World Data from Italy: Luspatercept Shows Promise in Transfusion-Dependent Beta-Thalassemia
Mostafa Faisal, associate professor of Adult Hematology and BMT, recently shared a post on use of Luspatercept on X:
”Luspatercept for Transfusion-Dependent Beta-Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy – The American Journal of Hematology.”
Read the full article here.
Following the approval of the drug in the U.S. and Europe—based on the findings of the randomized, placebo-controlled phase III BELIEVE trial—there remained a need to generate robust real-world evidence on its effectiveness, safety, and tolerability in routine clinical settings.
To address this, the impact of luspatercept treatment in a cohort of 231 individuals with TDT was assessed.
Published in the American Journal of Hematology, this new study presents one of the largest real-world cohorts examining the use of the drug in patients with transfusion-dependent beta-thalassemia (TDT) across Italy.
To learn more on new scientific advances in hematology, read Hemostasis Today.
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
-
Feb 16, 2026, 15:24Flora Peyvandi: Highlighting Overdose, Homicide, and Suicide as Causes of Maternal Death in the US
-
Feb 16, 2026, 14:53Wafaa Abougabal: Differential Diagnosis of Acute Neurologic Deficits and Stroke in PICU
-
Feb 16, 2026, 14:49Nayab Ahmed: Synthesis of ATP and Its Significance in Storage of Blood
-
Feb 16, 2026, 14:44Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES